FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381335181> ?p ?o ?g. }

• W4381335181 abstract "Abstract Background This study was conducted to identify factors associated with the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma and to confirm the real-world safety and effectiveness of pembrolizumab in Japanese patients. Methods This multicenter, observational, post-marketing surveillance was conducted over a 1-year observation period starting at pembrolizumab initiation (200-mg pembrolizumab every 3 weeks); data were collected from case report forms (3 months and 1 year). Safety measures included treatment-related adverse events and adverse events of special interest (AEOSI). Effectiveness assessments included tumor response, objective response rate (ORR), and disease control rate (DCR). Results Overall, 1293 patients were evaluated for safety and 1136 for effectiveness. At 12 months, the treatment-related adverse event incidence was 53.8% ( n = 696) and that of AEOSI was 25.0% ( n = 323). The most frequent AEOSI of any grade were endocrinological disorder (10.4%, n = 134), interstitial lung disease (ILD) (7.2%, n = 93), and hepatic function disorder (4.9%, n = 64). Multivariate analysis demonstrated that the risk of developing ILD was almost seven times greater (odds ratio 6.60) in patients with a comorbidity of ILD, and approximately twice as high in patients aged ≥ 65 years (odds ratio 2.24) and with smoking history (odds ratio 1.79). The ORR was 26.1% and the DCR was 50.7%. The ORR was 46.4% in patients with a Bellmunt risk score of 0 and decreased as the Bellmunt risk score increased. Conclusions This post-marketing surveillance confirmed the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma in the real-world setting." @default.
• W4381335181 created "2023-06-21" @default.
• W4381335181 creator A5011820209 @default.
• W4381335181 creator A5027566844 @default.
• W4381335181 creator A5032337115 @default.
• W4381335181 creator A5057797895 @default.
• W4381335181 creator A5058272688 @default.
• W4381335181 creator A5058912185 @default.
• W4381335181 creator A5066575603 @default.
• W4381335181 creator A5071455815 @default.
• W4381335181 date "2023-06-20" @default.
• W4381335181 modified "2023-09-27" @default.
• W4381335181 title "Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance" @default.
• W4381335181 cites W1752338025 @default.
• W4381335181 cites W1814430027 @default.
• W4381335181 cites W1820014750 @default.
• W4381335181 cites W2102116016 @default.
• W4381335181 cites W2103257412 @default.
• W4381335181 cites W2126548486 @default.
• W4381335181 cites W2132379894 @default.
• W4381335181 cites W2151488185 @default.
• W4381335181 cites W2154029052 @default.
• W4381335181 cites W2157244703 @default.
• W4381335181 cites W2475485257 @default.
• W4381335181 cites W2520200550 @default.
• W4381335181 cites W2588916311 @default.
• W4381335181 cites W2791260187 @default.
• W4381335181 cites W2903585288 @default.
• W4381335181 cites W2903848939 @default.
• W4381335181 cites W2988830956 @default.
• W4381335181 cites W3113007489 @default.
• W4381335181 cites W3118442307 @default.
• W4381335181 cites W3159611165 @default.
• W4381335181 cites W4213420312 @default.
• W4381335181 cites W4220741158 @default.
• W4381335181 cites W4226149113 @default.
• W4381335181 cites W4226375295 @default.
• W4381335181 cites W4234701175 @default.
• W4381335181 cites W4281486821 @default.
• W4381335181 cites W4288067023 @default.
• W4381335181 doi "https://doi.org/10.1186/s12885-023-10930-2" @default.
• W4381335181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37340317" @default.
• W4381335181 hasPublicationYear "2023" @default.
• W4381335181 type Work @default.
• W4381335181 citedByCount "0" @default.
• W4381335181 crossrefType "journal-article" @default.
• W4381335181 hasAuthorship W4381335181A5011820209 @default.
• W4381335181 hasAuthorship W4381335181A5027566844 @default.
• W4381335181 hasAuthorship W4381335181A5032337115 @default.
• W4381335181 hasAuthorship W4381335181A5057797895 @default.
• W4381335181 hasAuthorship W4381335181A5058272688 @default.
• W4381335181 hasAuthorship W4381335181A5058912185 @default.
• W4381335181 hasAuthorship W4381335181A5066575603 @default.
• W4381335181 hasAuthorship W4381335181A5071455815 @default.
• W4381335181 hasBestOaLocation W43813351811 @default.
• W4381335181 hasConcept C120665830 @default.
• W4381335181 hasConcept C121332964 @default.
• W4381335181 hasConcept C121608353 @default.
• W4381335181 hasConcept C126322002 @default.
• W4381335181 hasConcept C143095724 @default.
• W4381335181 hasConcept C143998085 @default.
• W4381335181 hasConcept C151956035 @default.
• W4381335181 hasConcept C156957248 @default.
• W4381335181 hasConcept C197934379 @default.
• W4381335181 hasConcept C2777701055 @default.
• W4381335181 hasConcept C2780057760 @default.
• W4381335181 hasConcept C61511704 @default.
• W4381335181 hasConcept C71924100 @default.
• W4381335181 hasConceptScore W4381335181C120665830 @default.
• W4381335181 hasConceptScore W4381335181C121332964 @default.
• W4381335181 hasConceptScore W4381335181C121608353 @default.
• W4381335181 hasConceptScore W4381335181C126322002 @default.
• W4381335181 hasConceptScore W4381335181C143095724 @default.
• W4381335181 hasConceptScore W4381335181C143998085 @default.
• W4381335181 hasConceptScore W4381335181C151956035 @default.
• W4381335181 hasConceptScore W4381335181C156957248 @default.
• W4381335181 hasConceptScore W4381335181C197934379 @default.
• W4381335181 hasConceptScore W4381335181C2777701055 @default.
• W4381335181 hasConceptScore W4381335181C2780057760 @default.
• W4381335181 hasConceptScore W4381335181C61511704 @default.
• W4381335181 hasConceptScore W4381335181C71924100 @default.
• W4381335181 hasIssue "1" @default.
• W4381335181 hasLocation W43813351811 @default.
• W4381335181 hasLocation W43813351812 @default.
• W4381335181 hasLocation W43813351813 @default.
• W4381335181 hasOpenAccess W4381335181 @default.
• W4381335181 hasPrimaryLocation W43813351811 @default.
• W4381335181 hasRelatedWork W1580426574 @default.
• W4381335181 hasRelatedWork W2016483411 @default.
• W4381335181 hasRelatedWork W2024025088 @default.
• W4381335181 hasRelatedWork W2089620537 @default.
• W4381335181 hasRelatedWork W2118847041 @default.
• W4381335181 hasRelatedWork W2275480158 @default.
• W4381335181 hasRelatedWork W2552874931 @default.
• W4381335181 hasRelatedWork W4238089809 @default.
• W4381335181 hasRelatedWork W4315650970 @default.
• W4381335181 hasRelatedWork W4386083912 @default.
• W4381335181 hasVolume "23" @default.
• W4381335181 isParatext "false" @default.
• W4381335181 isRetracted "false" @default.

• next